Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability
Retrieved on:
Thursday, June 1, 2023
ASC, CRISPR, CELU, Placenta, Gene, Thrombogenicity, Diabetic foot ulcer, ISCT, Immunomodulation, Instituto de Biologia Molecular e Celular, Cell, Multiple sclerosis, FSHD, Stem cell, Microsoft Exchange Server, Thrombosis, MSC, Facioscapulohumeral muscular dystrophy, TF, Data, Blood, Abdominal ultrasonography, Phenotype, International Society, Safety, Pharmaceutical industry, Vaccine, Cytotherapy
FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today the online publication of preclinical data in Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT).
Key Points:
- The paper, “Characterization of CRISPR/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic effects,” (Huang, et al.
- )1 examined methods to reduce the tissue factor expressed by allogeneic stromal cells (ASCs), which has been regarded as a safety concern in clinical applications as it may trigger thrombosis when ASCs are administered intravenously.
- Thrombogenic risk has been identified in association with intravenous administration of mesenchymal stem cells (MSCs), both allogeneic and autologous.
- These cells express procoagulant activity linked to the expression of tissue factor that, when in contact with blood, initiates coagulation.